- Home
- IPAR vs TGTX Comparison
IPAR vs TGTX Comparison
Compare IPAR & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPAR
- TGTX
- Stock Information
- Founded
- IPAR 1982
- TGTX 1993
- Country
- IPAR United States
- TGTX United States
- Employees
- IPAR N/A
- TGTX N/A
- Industry
- IPAR Package Goods/Cosmetics
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- IPAR Consumer Discretionary
- TGTX Health Care
- Exchange
- IPAR Nasdaq
- TGTX Nasdaq
- Market Cap
- IPAR 3.9B
- TGTX 4.2B
- IPO Year
- IPAR 1988
- TGTX 1995
- Fundamental
- Price
- IPAR $107.24
- TGTX $31.87
- Analyst Decision
- IPAR Strong Buy
- TGTX Strong Buy
- Analyst Count
- IPAR 4
- TGTX 4
- Target Price
- IPAR $162.00
- TGTX $42.50
- AVG Volume (30 Days)
- IPAR 234.1K
- TGTX 2.0M
- Earning Date
- IPAR 11-05-2025
- TGTX 11-03-2025
- Dividend Yield
- IPAR 2.97%
- TGTX N/A
- EPS Growth
- IPAR 14.29
- TGTX N/A
- EPS
- IPAR 5.02
- TGTX 0.36
- Revenue
- IPAR $1,458,888,000.00
- TGTX $454,069,000.00
- Revenue This Year
- IPAR $5.62
- TGTX $82.58
- Revenue Next Year
- IPAR $4.30
- TGTX $44.99
- P/E Ratio
- IPAR $21.50
- TGTX $89.78
- Revenue Growth
- IPAR 7.04
- TGTX 30.96
- 52 Week Low
- IPAR $97.65
- TGTX $21.16
- 52 Week High
- IPAR $148.15
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- IPAR 33.94
- TGTX 55.16
- Support Level
- IPAR $111.62
- TGTX $31.34
- Resistance Level
- IPAR $116.11
- TGTX $32.47
- Average True Range (ATR)
- IPAR 2.97
- TGTX 1.12
- MACD
- IPAR -0.25
- TGTX 0.52
- Stochastic Oscillator
- IPAR 10.65
- TGTX 69.10
About IPAR Inter Parfums Inc.
Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations.. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.